What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...